Cerebral Venous Sinus ThrombosisCCCNCT03919305
Cerebral Venous Thrombosis Cohort Study in China Mainland
An observational study of Cerebral Venous Sinus Thrombosis and Deep Cerebral Vein Thrombosis, run by Capital Medical University at 1 site in China.
Trial summary
This study was aimed to reveal the clinical features,natural history of the diseases and current therapeutic situations of cerebral venous thrombosis (CVT) in China mainland. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cerebral Venous Sinus Thrombosis, Deep Cerebral Vein Thrombosis, Cortical Vein Thrombosis
- How many people
- 3,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2019to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis.
Who may be able to join
- Cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis diagnosed by digital subtraction angiography (DSA), magnetic resonance venography (MRV), computed tomography venography (CTV) or high-resolution magnetic resonance imaging (HR-MRI).
Who cannot join
- None of the patient, trustee or immediate family members signed the informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Xuanwu Hospital, Capital Medical University
Beijing
Min Li, MD, PhD
About this study
This study was aimed to reveal the clinical features,natural history of the diseases and current therapeutic situations of cerebral venous thrombosis (CVT) in China mainland. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the biomarkers for CVT.
Read the detailed description
cerebral venous thrombosis (CVT) is caused by a clot in the cerebral vein, which resulted in an obstruction of the blood outflow. CVT mainly includes cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis. However, the epidemiological features of CVT in China mainland remained obscure. This study was aimed to establish a multicenter cohort recruiting patients with CVT across 31 provinces and municipalities in China mainland. Clinical features,natural history of the diseases and current therapeutic situations will be analyzed to reveal the epidemiological features of CVT. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the biomarkers for CVT. Patients will be followed-up at 1, 3, 6, 12 months from baseline to evaluate the clinical prognosis and therapeutic outcomes.
- Keywords
- Cerebral venous sinus thrombosis, Deep cerebral vein thrombosis, Cortical vein thrombosis, Cohort study, Real world evidence, Observational study, China mainland, Cerebral venous system thrombosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Death rate
A combination of death form of all causes
Measured: 1 year from baseline
Functional independence
Defined as modified Rankin score (0-5) equal to or lower than 2
Measured: 1 year from baseline
Recurrence of cerebral venous sinus thrombosis, deep cerebral venous thrombosis and cortical vein thrombosis
Diagnosed by DSA, MRV, CTV or HR-MRI
Measured: 1 year from baseline
Incidence of hemorrhagic complication
Extracranial hemorrhage (fall in hemoglobin of 2 gram/dl or more within 48 hours) or intracranial hemorrhage
Measured: 1 year from baseline
Incidence of sinus wall rupture
Measured: 1 year from baseline
Incidence of acute ischemic stroke
Measured: 1 year from baseline
Incidence of acute myocardial infarction
Measured: 1 year from baseline
Incidence of pulmonary embolism
Measured: 1 year from baseline
Incidence of deep venous thrombosis
Measured: 1 year from baseline
Secondary outcomes (2)
Incidence of epilepsy
Measured: 1 year from baseline
Incidence of allergic reaction
Measured: 1 year from baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2019
- Study start1 Jan 2019
- Primary completion31 Dec 2025
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cerebral Venous Sinus ThrombosisStudies of the same condition, open and under way.
- More trials run by Capital Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Capital Medical University
- Sponsor type
- University, hospital or other
- Collaborators
- Beijing Municipal Science & Technology Commission
- Responsible party
- Principal investigator, Ji Xunming,MD,PhD, Capital Medical University
- Investigators
- Xunming Ji, MD, PhD, Principal investigator, Xuanwu Hospital, Beijing
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03919305
- Sponsor's protocol ID
- CVT-China
- Acronym
- CCC
- Status last verified
- May 2026
- First submitted
- 3 Apr 2019
- Last updated
- 2 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cerebral Venous Thrombosis Cohort Study in China Mainland
- ClinicalTrials.gov ID
- NCT03919305
- Acronym / sponsor ID
- CCC / CVT-China
- Keywords
- Cerebral venous sinus thrombosis, Deep cerebral vein thrombosis, Cortical vein thrombosis, Cohort study, Real world evidence, Observational study, China mainland, Cerebral venous system thrombosis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- Capital Medical UniversityUniversity, hospital or other
- Collaborators
- Beijing Municipal Science & Technology Commission
- Study start
- 1 Jan 2019 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 18 Apr 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was aimed to reveal the clinical features,natural history of the diseases and current therapeutic situations of cerebral venous thrombosis (CVT) in China mainland. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the biomarkers for CVT.
Detailed description
cerebral venous thrombosis (CVT) is caused by a clot in the cerebral vein, which resulted in an obstruction of the blood outflow. CVT mainly includes cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis. However, the epidemiological features of CVT in China mainland remained obscure. This study was aimed to establish a multicenter cohort recruiting patients with CVT across 31 provinces and municipalities in China mainland. Clinical features,natural history of the diseases and current therapeutic situations will be analyzed to reveal the epidemiological features of CVT. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the biomarkers for CVT. Patients will be followed-up at 1, 3, 6, 12 months from baseline to evaluate the clinical prognosis and therapeutic outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis.
Key inclusion criteria (1 listed)
- Cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis diagnosed by digital subtraction angiography (DSA), magnetic resonance venography (MRV), computed tomography venography (CTV) or high-resolution magnetic resonance imaging (HR-MRI).
Key exclusion criteria (1 listed)
- None of the patient, trustee or immediate family members signed the informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Death rate
Time frame: 1 year from baseline
A combination of death form of all causes
Functional independence
Time frame: 1 year from baseline
Defined as modified Rankin score (0-5) equal to or lower than 2
Recurrence of cerebral venous sinus thrombosis, deep cerebral venous thrombosis and cortical vein thrombosis
Time frame: 1 year from baseline
Diagnosed by DSA, MRV, CTV or HR-MRI
Incidence of hemorrhagic complication
Time frame: 1 year from baseline
Extracranial hemorrhage (fall in hemoglobin of 2 gram/dl or more within 48 hours) or intracranial hemorrhage
Incidence of sinus wall rupture
Time frame: 1 year from baseline
Incidence of acute ischemic stroke
Time frame: 1 year from baseline
Incidence of acute myocardial infarction
Time frame: 1 year from baseline
Incidence of pulmonary embolism
Time frame: 1 year from baseline
Incidence of deep venous thrombosis
Time frame: 1 year from baseline
2 secondary outcomes
Incidence of epilepsy
Time frame: 1 year from baseline
Incidence of allergic reaction
Time frame: 1 year from baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
Related trials for Cerebral Venous Sinus Thrombosis
RecruitingObservational study
Danang Cerebral Venous Thrombosis Registry
Cerebral Venous Sinus Thrombosis, Stroke
Recruiting
MENA Regional Endovascular Intervention for Venous Cerebral Venous Sinus Thrombosis
Cerebral Venous Sinus Thrombosis
Active, not recruiting
Endovascular Treatment or Standard Medical Care for Cerebral Venous Sinus Thrombosis(ESCORT)
Cerebral Venous Sinus Thrombosis
Not yet recruitingObservational study
Glymphatic Function and White Matter Integrity in Cerebral Venous Disorders
Cerebral Venous Sinus Thrombosis
RecruitingObservational study
The Norwegian Cerebral Venous Thrombosis Study
Cerebral Vein Thrombosis, Cerebral Venous Sinus Thrombosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xunming Ji, MD, PhD principal investigator
Xuanwu Hospital, Beijing
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cerebral Venous Sinus Thrombosis and Deep Cerebral Vein Thrombosis, run by Capital Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Min Li, MD, PhD (+86-18701519698, 812879698@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Death rate (time frame: 1 year from baseline). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026; AzTrials last refreshed its copy on 7 Nov 2026.